Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stentor Inc.

This article was originally published in Start Up

Executive Summary

Stentor offers technology for web-enabled transmission of images. The company claims that its proprietary image browser, because it can retrieve just those areas needed by the viewer, obviates the need for the image compression that compromises the quality of other Internet-based image distribution systems.

You may also be interested in...



Imaging and the Web

In the ten years or so since picture archiving and communications systems (PACS) were introduced, only 15% of hospitals in the US have implemented them in their radiology departments; the vast majority of hospitals handle most images as they have for years--on film and manually. The reasons are many, but cost is a big factor. Hospitals simply don't have money to pay for expensive PACS. A new business model, the application service provider (ASP) offers a solution. ASPs centralize alot of PACS services, serving multiple clients at once, and archiving digital images off-site at a central location. Hospitals pay on a per transaction basis and avoid the upfront costs of installing capital equipment. The web has made this possible because images can be transmitted over the Internet to off-site storage locations.

BrightGene Bets On Remdesivir Amid Patent Questions

Despite many uncertainties, Suzhou-based BrightGene sees a bet on generic remdesivir worthy of a $700,000 investment.

QUOTED. 17 February 2020. Ralph Ives.

The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.   

Topics

Related Companies

UsernamePublicRestriction

Register

MT037102

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel